We assessed the long-term outcome of patients with relapsed acute myeloid (n ¼ 86) or acute lymphoid leukemia (n ¼ 66), undergoing an allogeneic hemopoietic stem cell transplantation in our unit. The median blast count in the marrow was 30%. Conditioning regimen included total body irradiation (TBI) (10-12 Gy) in 115 patients. The donor was a matched donor (n ¼ 132) or a family mismatched donor (n ¼ 20). Twenty-two patients (15%) survive disease free, with a median follow-up of 14 years: 18 are off medications. The cumulative incidence of transplant related mortality is 40% and the cumulative incidence of relapse related death (RRD) is 45%. In multivariate analysis of survival, favorable predictors were chronic graft-versus-host disease (GvHD) (P ¼ 0.0003), donor other than family mismatched (P ¼ 0.02), donor age less than 34 years (P ¼ 0.02) and blast count less than 30% (P ¼ 0.07). Patients with all four favorable predictors had a 54% survival. In multivariate analysis of relapse, protective variables were the use of TBI (P ¼ 0.005) and cGvHD (P ¼ 0.01). This study confirms that a fraction of relapsed leukemias is cured with an allogeneic transplant: selection of patients with a blast count o30%, identification of young, human leukocyte antigen-matched donors and the use of total body radiation may significantly improve the outcome.
Introduction
Allogeneic hemopoietic stem cell transplantation (HSCT) has been shown to produce long-term survival in approximately 10-15% of patients with advanced leukemia. 1 Several more recent reports have confirmed these findings:
Sierra et al. [2] [3] [4] have analyzed patients with primary leukemia allografted from unrelated donors in relapse (n ¼ 94) or with primary induction failure (n ¼ 14) and have compared the outcome with 66 patients grafted in remission. In multivariate analysis, cell dose and remission status had a significant impact on leukemia-free survival; for patients grafted in relapse the overall 10-year survival was 18%, but if marrow blasts were less than 30% at the time of transplant survival was close to 40%. 2 It is interesting to note that the effect of cell dose was seen in remission patients but not in relapse patients. Leukemia relapse remained a significant problem, being 40% for patients with less than 30% blasts, but reaching 80% for patients with a higher marrow count at transplant.
An alternative approach has been recently reported in a series of 75 patients most (n ¼ 59) with active leukemia at transplant. The program included cytoreduction with a course of chemotherapy, followed after 3 days by total body irradiation (TBI) (4 Gy), cyclophosphamide (CY) and an allogeneic HSCT. 5 The overall 2-year survival was 42%, which is better than the usual 10-20% seen in other series. Targeted marrow irradiation with 131 I-loaded antibodies has also been explored in an attempt to reduce leukemia relapse, which remains the major problem of allogeneic transplantation for advanced leukemia. [6] [7] The issue of allogeneic transplantation for patients with relapsed leukemia is relevant because of the large number of potential candidates, the high risk of complications and cost/benefit considerations. In the present report, we analyze our experience with 152 advanced leukemia patients allografted between 1977 and 2004, testing for variables predicting outcome.
Patients and methods

Patients
One hundred and fifty-two patients with relapsed leukemia received an allogeneic HSCT in our unit between 1977 and 2004: median year of transplant was 1995 and minimum follow-up for surviving patients 1 year. Table 1 outlines clinical characteristics of the patients. The median blast count was 30% (7-100%) and the median peripheral blood (PB) blast count was 2% (0-100%). These were consecutive allogeneic transplants performed between 1977 and 2004, for patients with relapsed de novo acute myeloid (AML) (n ¼ 86) or acute lymphoid leukemia (ALL) (n ¼ 66).
Conditioning regimens
Major conditioning regimens are outlined in Table 1 . Patients received either CY 60 mg/kg/day Â 2 and TBI (10-12 Gy in fractionated doses) 8 or CY combined with busulfan (BU) or thiotepa as described. 9 Stem cell source and stem cell harvest Bone marrow (BM) was the stem cell (SC) source in the majority of patients (82%). PB was given in the remaining 18%. Marrow from unrelated donors was provided by the Italian National Marrow Donor Registry (IBMDR). Family mismatched donors were mismatched for one human leukocyte antigen (HLA) in 11 cases and for two to three antigens in nine cases. Unrelated donors were matched according to the criteria at the time of transplant (which may indicate that some would have been typed as mismatched for one or more alleles with present technology).
GvHD prophylaxis
All patients received GvHD prophylaxis: methotrexate (MTX) alone was given in 15 patients, cyclosporin (Cy)A alone in 35, MTX þ CyA in 90 and ex vivo T cell depletion (TCD), with Cy post-graft, in 12. Ex vivo TCD was performed with CAMPATH in the bag (n ¼ 4), an anti-CD26 antibody in the bag (n ¼ 4) or CD34 þ cell selection with Cellpro (n ¼ 4). 10 A number of patients grafted from unrelated or family mismatched allografts (n ¼ 35) received rabbit anti-thymocyte globulin (Thymoglobuline, Genzyme, Boston, MA, USA) in the conditioning regimen, in doses ranging from 7.5 to 15 mg/kg as described elsewhere.
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Cytomegalovirus monitoring and pre-emptive therapy Patients were monitored for cytomegalovirus antigenemia as of 9 January, 1991 (UPN 590) and received pre-emptive therapy with foscarnet or ganciclovir or combined treatment.
Intravenous immunoglobulin
High-dose intravenous IgG were given at doses ranging between 100 and 400 mg/kg/week until day 100.
Gut decontamination
Gut decontamination was achieved with oral neomicin and colimicin in the 1980s and with quinolones in the 1990s. We are currently using ciprofloxacin orally until the patient becomes febrile.
Antifungal prophylaxis therapy
Oral nystatin and then mepartricin (an absorbable polyene) was used until the advent of fluconazole, which is now standard fungal prophylaxis until day þ 75. Secondary prophylaxis with amphotericin or voriconazole is currently given if the patient comes to transplant with a known history of aspergillum infection.
Statistical analysis
Patient data were collected prospectively and updated at each outpatient visit. The data were analyzed with the NCSS package. Comparisons were carried out using the w 2 test for categorical variables and the non-parametric Mann-Whitney test for continuous variables. End point for survival analysis was death without relapse (transplant related mortality, TRM), death due to relapse (relapse related death, RRD) or death due to any cause. The survival curves for TRM and RRD were estimated using the cumulative incidence (CI) accounting for the fact that these end points are competing causes of death. Univariate and multivariate survival analyses were carried out using the Cox proportional hazard model. Table 2 outlines major transplant outcome. Engraftment as assessed by neutrophil increase above 0.5 Â 10 9 /l was achieved in the majority of patients, with timing ranging from 8 to 35 days from transplant. Acute GvHD grade II-IV developed in 44, 40 and 46 of patients grafted, respectively, from matched siblings, family mismatched or unrelated donors ( Table 2 ). The overall actuarial survival at 20 years is 14% (Figure 1 ), the CI of TRM is 40% and the CI of RRD is 45%.
Results
Transplant outcome
Univariate analysis on survival
We then looked at factors predicting survival in univariate analysis (Table 3 ). In univariate analysis donor age less than 34 (median age in years), other than family mismatched, a marrow blast count less than 30%, a PB count less than 2%, the use of TBI, GvHD prophylaxis other than TCD, the use of CyA alone compared with /kg), donor gender, female donor in male recipient, were not predictive of survival. When considering only transplant variables (donor age o34 years, other than family mismatched, the use of TBI, CyA alone for GvHD prophylaxis and no ex vivo TCD), patients with one to five of these variables had a survival of 0, 4, 10, 21 and 33%, respectively (P ¼ 0.0002). The improved outcome was due to a reduction of TRM (from 90% in patients with one favorable factor, to 17% in patients with all five; P ¼ 0.02); whereas RRD remained constant between 39 and 50% (P ¼ 0.2). Survival of patients stratified for donor type were as follows: 18% for matched sibling donors (n ¼
Multivariate analysis on survival
In multivariate analysis on survival, a donor other than family mismatched and a marrow blast count less than 30% retained a significant predictive effect ( Table 4 ). The actuarial 20-year survival of patients with 0 (n ¼ 11), one (n ¼ 75) or both these favorable variables (n ¼ 66) was 0%, 5% and 26%, respectively (Po0.00001) (Figure 2 ). If HSCT for relapsed acute leukemia A Bacigalupo et al chronic GvHD was introduced in the model (only for 94 patients surviving 100 days), then donor age and donor type together with chronic GvHD were significant predictors, with marrow blasts having a borderline effect (P ¼ 0.07) ( Table 3 ). The actuarial survival of patients with one (n ¼ 7), two (n ¼ 35), three (n ¼ 34) or all four (n ¼ 18) favorable factors is respectively 0, 11, 24 and 54% ( Figure 3 ). This is because of decreased RRD (respectively 100, 71, 52 and 44%, P ¼ 0.02) rather than reduced TRM (respectively 0, 20, 20 and 0%, P ¼ 0.1).
Causes of death
The most common cause of death is leukemia relapse (45%). The overall TRM is 40%: most frequent complications are infections (21%) followed by GvHD (9%) and multiorgan failure (5%).
Long-term survivors
Twenty-two patients aged 31 years (range 15-51), 12 males and 10 females, survive between 1.8 and 24 years (median 14 years) after transplant: 15 are AML and seven are ALL; they were grafted at a median interval of 300 days from diagnosis (range 65-3958 days) from a matched sibling donor (n ¼ 18), an unrelated donor (n ¼ 3) or a twin (n ¼ 1); their median blast count in the marrow was 20% (7-70%) and their median PB blast count was 2% (0-50%). Twenty (90%) of these survivors were prepared with TBI and 78% have developed chronic GvHD. We have followed up these 22 patients in the previous year: 18 are off medications, leading a normal life without signs of chronic GvHD. Four patients have developed second tumors (two skin, one thyroid, one mouth).
Discussion
We have confirmed in this study that allogeneic marrow transplantation can produce long-term survival in a minority of patients with relapsed leukemia; we have also shown that patients with a marrow blast count not exceeding 30%, grafted from young donors, and especially if they develop chronic GvHD have significantly superior outcome.
As to the first finding, this had been shown many years ago by the Seattle group 1 and is therefore a well-established notion in the transplant community:
2-7 5-15% of patients allografted with advanced leukemia become long-term survivors. Nevertheless, several questions remain open: have these patients benefited from improved supportive care and therefore has the outcome improved with time; secondly, can we identify transplant procedures that may prove relatively more successful or identify patients characteristics which may predict a better outcome.
In this study, we show that changes in transplant protocols have not made these transplants more successful and survival has remained unchanged over a period of three decades. This is in keeping with a previous and more comprehensive analysis focused on transplant mortality, 12 in which we have shown significant improvement with time only for patients with early leukemia. 12 Infections remain a major problem, possibly because of prolonged chemotherapy, neutropenia and infections to which patients are exposed before transplant. As to the identification of patients at better prognosis, we found several transplant related, donor related and disease related variables that predicted outcome in univariate analysis. All of these variables, with the exclusion of TBI and chronic GvHD were associated with improved survival because of reduced TRM. The use of TBI and more so the development of chronic GvHD were instead associated with reduced RRD (RR ¼ 0.50, P ¼ 0.008 and RR ¼ 36, P ¼ 0.0002, respectively). In multivariate analysis, we found that survival was predicted by blast count in the marrow and donor type: transplants were more successful if the blast count in the marrow was less than 30% (median) and if the donor was an HLA identical or unrelated matched donor. When the analysis was restricted to patients alive on day 100 (n ¼ 94) then, chronic GvHD was the strongest predictor of survival, owing to a significant reduction of the risk of RRD. These data suggest that we can improve results by better selection of patients. Still, many individuals will come to transplant in poor hematologic condition and with no HLA-matched donor; the latter should either not be transplanted or entered in prospective trials looking at conditioning regimens, GvHD prophylaxis or alternative SC sources.
As to the conditioning regimens it has been difficult, in prospective randomized trials, to show the superiority of one specific conditioning regimen: in one trial survival was quite similar in patients with advanced leukemia receiving BU cyclophopshamide, or VP16 and TBI. 4 Similarly, studies using additional marrow radiation have been shown to be feasible, but have not been tested prospectively against conventional TBI and cannot be said to be superior to the latter. 6, 7 In the few prospective studies testing the effect of intensified regimens, these were associated with less leukemia relapse but higher transplant mortality, leading to comparable overall survival. 13 Nevertheless, some studies show differences; and for AML leukemia in remission, radiation based regimens have been shown to be superior to BU-based regimens, in prospective randomized trials. 14 The combination of a course of chemotherapy before the conditioning regimen also seems to have produced promising results. 5 GvHD prophylaxis plays a major role in control of the underlying disease, as shown by two separate studies proving that low-dose Cy significantly reduces leukemia relapse and improves survival in patients with AML or ALL, in both children and adults. 15, 16 In the first study, the difference in relapse was 20 vs 59% for patients given CyA 1 mg/kg or 5 mg/kg in the first 10 days of transplant. 15 In the second study, the difference in relapse was 15 vs 41% in children with ALL given CyA 1 mg/kg or 3 mg/kg. 16 This is probably owing to GvHD-mediated graft vs leukemia effect, which is possibly promoted by reducing posttransplant immunosuppression. It is surprising that, despite these two randomized studies and a 10-year follow-up of the first study, 17 most centers still use 3-5 mg/kg of CyA in the early post-transplant period. We have moved all of our programs to low-dose (1 mg/kg) CyA, but this may not be sufficient when treating patients with relapsed leukemia as reported in the present study. One wonders whether omitting CyA altogether, in the first week of transplant, may improve GvL and reduce leukemia relapse. Different SC source, with different degree of HLA matching, are currently available. In this study, we found that family HLA-mismatched donors did worse than HLAmatched related or unrelated donors. However, these transplants were all performed using BM or PB and the number of family-mismatched donors was small. The use of cord blood, double cord and mixed cord/haplo family grafts, have recently opened new opportunities especially for the patients with advanced leukemia who cannot wait a long time for the identification of a suitable donor. [18] [19] [20] In conclusion, allogeneic transplantation in patients with relapsed leukemia remains a complex medical procedure with high risk of failure. Nevertheless, 20-year survival with cure of the underlying leukemia, can be achieved in some patients who may enjoy a good quality of life. The chance of cure increases with young HLA-matched family or unrelated donors and especially when chronic GvHD occurs. Several strategies may potentially improve the outcome of allogeneic transplants in these patients, including changes in conditioning regimens, GvHD prophylaxis and SC sources: these need to be explored in prospective clinical trials.
